Progress in treatment of relapsed/refractory peripheral T-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 83-86, 2020.
Article
in Zh
| WPRIM
| ID: wpr-862805
Responsible library:
WPRO
ABSTRACT
The peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphoma. The overall prognosis is poor with high risk of relapse after the first-line treatment. The 61st American Society of Hematology (ASH) Annual Meeting has covered many treatment advances of PTCL, especially for relapsed/refractory patients. The main contents include histone deacetylase inhibitors (HDACi), farnesyl transferase (FT) inhibitors, dual inhibitors of SYK/JAK signaling pathway, PI3K inhibition agent, programmed death 1 (PD-1) monoclonal antibody, anti-CD38 monoclonal antibody, and EZH1/2 dual inhibitor. New protocols and drugs have brought hope for relapsed/refractory PTCL patients.
Full text:
1
Index:
WPRIM
Type of study:
Guideline
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2020
Type:
Article